ORLANDO—The 4Kscore, an algorithmic analysis of data from a blood test that combines four kallikrein assays with clinical information to identify the probability of high-grade prostate tumors, could dramatically reduce the number of unnecessary prostate biopsies, according to a multi-institutional prospective study (Abstract 1) presented during the 2015 Genitourinary Cancers Symposium.1
“The 4Kscore demonstrated excellent accuracy in detecting high-grade prostate cancer,” reported lead study author Sanoj Punnen, MD, of the Sylvestor Comprehensive Cancer Center and Department of Urology, University of Miami in Miami, FL. “It is a useful tool in selecting men who are likely to have high-grade disease and most likely to benefit from a prostate biopsy versus those men with no cancer or indolent cancer.”
Prostate cancer screening is associated with improved cancer-specific mortality “but comes at a high cost,” Dr. Punnen noted. “Saving one man’s life requires that 1,068 men be screened and 48 undergo treatment…. Many men will have to undergo unnecessary testing,” he said. “Biopsy entails significant risks of urinary incontinence and emotional stress.”
The 4Kscore has been “well validated in multiple retrospective European cohorts,” Dr. Punnen reported, but it has not previously been tested prospectively or in the United States.
Read the entire article on Cancer Therapy Advisor.